Product news

Share this article:

Sciele Pharma said the FDA has approved all four dosage strengths of the new Sular formulation, which utilizes SkyePharma's patented Geomatrix technology and provides a lower dose of Sular for each of its current doses. Sciele expects to launch the new Sular formulation during the first quarter of 2008.

Depomed said the FDA has approved 1000 mg strength tablets of Glumetza for patients with type 2 diabetes.

Drug developer Watson Pharmaceuticals said the FDA approved its generic version of Dey's respiratory condition treatment DuoNeb. The drug treats breathing difficulty in patients with chronic obstructive pulmonary disease. Watson plans to start selling the generic drug immediately.

Cell Therapeutics Inc. (CTI) announced that it has completed its acquisition of Zevalin (ibritumomab tiuxetan) from Biogen Idec, giving CTI sole responsibility for marketing, sales, and development of the drug in the US. Zevalin will continue to be sold outside the US by Bayer Schering under an agreement between Biogen Idec and Bayer Schering. Approved in 2002 to treat patients with relapsed indolent non-Hodgkin's lymphoma, Zevalin was the first radioimmunotherapy to be approved by the FDA. In 2006, Biogen Idec reported $16.4 million in US Zevalin sales.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.